Nuvalent, Inc. (NUVL) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jun 18Jun 24Jun 29Jul 2Jul 8Jul 13Jul 16Jul 21

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−25.4x

Market Cap

$9.79B

MomentumView details →

1D Return

+0.00%

YTD Return

+23.23%

RSI (14)

67.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−25.4x

Market Cap

$9.79B

RSI (14)

67.6

MomentumView details →

1D Return

+0.00%

YTD Return

+23.23%

SummaryUpdated Mar 1, 2026

Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Cambridge, Massachusetts. The company went public in July 2021 and focuses on developing precision oncology therapies for cancer patients. Nuvalent specializes in creating targeted inhibitors for specific genetic mutations that drive certain types of cancer, particularly lung cancers with ROS1 and ALK gene fusions.

Ask drillr about Nuvalent, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−38.32%

ROA (TTM)

−33.81%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−38.04%

FCF YoY

−53.48%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−48.85%

EBITDA YoY

−7.10%

EarningsView details →

EPS (Actual)

−$1.39

EPS Surprise

−2.96%

Beats (12Q)

2/12

Next Q EPS Est

—

Avg Surprise (4Q)

−7.98%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

16.14x

Quick Ratio

16.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−450.07M

Op. CF (TTM)

−312.79M

Latest newsMore news →

GSK completes the acquisition of US-based cancer specialist Nuvalent for nearly £8 billion.38d ago

The US FDA approved GSK's Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor.44d ago

Similar companies

Ascletis Pharma Inc.01672.HK Kymera Therapeutics, Inc.KYMR Ionis Pharmaceuticals, Inc.IONS Praxis Precision Medicines, Inc.PRAX GenFleet Therapeutics (Shanghai) Inc.02595.HK Abivax S.A.ABVX Find similar companies →

Latest newsMore news →

GSK completes the acquisition of US-based cancer specialist Nuvalent for nearly £8 billion.38d ago The US FDA approved GSK's Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor.44d ago